Safety and Efficacy of Belimumab in Patients with Lupus Nephritis
Clin J Am Soc Nephrol. 2022;17:1620–1630 doi: 10.2215/CJN.02520322
Following approval of belimumab (based on the results of the BLISS-LN study) in the United States and Europe, as the first biologic agent for the treatment of adult patients with active lupus nephritis, Furie, et al. investigate adding or continuing belimumab treatment beyond 2 years, in this open-label extension study.